Search
Now showing items 1-7 of 7
Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
(
Wiley Open Access
, 2019 , Article)
Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy, which often presents at an advanced stage. A proportion of SDC are characterized by HER2 amplification and/or overexpression of androgen receptor ...
Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity.
(
MDPI
, 2019 , Article)
Breast cancer is the most frequent cause of cancer-related deaths among women worldwide. It is classified into four major molecular subtypes. Triple-negative breast cancers (TNBCs), a subgroup of breast cancer, are defined ...
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
(
Lippincott, Williams & Wilkins
, 2019 , Article)
The breast is a rare site for metastases, and their molecular characteristics have not been studied yet. Intrinsic molecular genetics, cancer characteristics, and breast tissue immune responses in diverse metastases to the ...
Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets.
(
MDPI
, 2020 , Article)
Breast cancer is one of the most prevalent diseases among women worldwide and is highly associated with cancer-related mortality. Of the four major molecular subtypes, HER2-positive and triple-negative breast cancer (TNBC) ...
Immunohistochemistry-Enabled Precision Medicine
(
Springer, Cham
, 2019 , Book chapter)
Immunohistochemistry (IHC) can be applied to diagnostic aspects of pathologic examination to provide aid in assignment of lineage and histologic type of cancer. Increasingly, however, IHC is widely used to provide prognostic ...
PD-L1 testing by immunohistochemistry in Immuno-Oncology.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2022 , Article Review)
Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. ...
An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
(
Multidisciplinary Digital Publishing Institute (MDPI)
, 2023 , Article)
Merkel cell carcinoma (MCC) is primarily a disease of the elderly Caucasian, with most cases occurring in individuals over 50. Immune checkpoint inhibitors (ICI) treatment has shown promising results in MCC patients. ...